In fact, it will be highly interesting to investigate the occurrence of CLS in sub-groups (i.e., HER2 over-expressing as well as triple negative compared to ER + tumors) according to overweight/obesity that was not possible in the current study due to the low numbers of non-ER + patients. This evidence concerns the gene ERBB2 and obesity disorder.